findmyKOL
Clinical trialNCT07094685RecruitingPhase 2Interventional

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

SponsorUniversity of Michigan Rogel Cancer CenterEnrollment28Advanced Head and Neck Squamous Cell CarcinomaResectable Head and Neck Squamous Cell CarcinomaStage II Head and Neck Cutaneous Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A bispecific monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan, United States

    Paul L. Swiecicki
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ivonescimab
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
18 Nov 2025
Primary completion
1 Aug 2027
Completion
1 Nov 2030
Last update posted
26 Jun 2026
Registered enrollment
28
Registry id
NCT07094685
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.